X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1617) 1617
humans (1113) 1113
male (685) 685
animals (655) 655
female (540) 540
benzothiazoles (525) 525
benzothiazoles - therapeutic use (448) 448
benzothiazoles - pharmacology (426) 426
pharmacology & pharmacy (387) 387
pramipexole (341) 341
benzothiazoles - chemistry (333) 333
middle aged (329) 329
dopamine agonists - therapeutic use (297) 297
mice (287) 287
clinical neurology (284) 284
aged (279) 279
parkinson disease - drug therapy (266) 266
chemistry, medicinal (251) 251
rats (249) 249
thiazoles - therapeutic use (231) 231
dose-response relationship, drug (216) 216
neurosciences (216) 216
adult (210) 210
antiparkinson agents - therapeutic use (209) 209
parkinson's disease (194) 194
analysis (181) 181
biochemistry & molecular biology (179) 179
benzothiazole (175) 175
treatment outcome (159) 159
cell line, tumor (158) 158
antioxidants - pharmacology (155) 155
antioxidants (154) 154
cancer (151) 151
apoptosis (146) 146
benzothiazoles - adverse effects (145) 145
benzothiazoles - administration & dosage (142) 142
dopamine (138) 138
restless legs syndrome - drug therapy (135) 135
thiazoles - pharmacology (135) 135
sulfonic acids - chemistry (129) 129
in-vitro (123) 123
double-blind (121) 121
structure-activity relationship (120) 120
antineoplastic agents - pharmacology (119) 119
levodopa - therapeutic use (118) 118
derivatives (117) 117
article (111) 111
dopamine agonists - adverse effects (110) 110
restless legs syndrome (108) 108
psychiatry (107) 107
disease models, animal (106) 106
oxidative stress (105) 105
double-blind method (103) 103
parkinsons-disease (103) 103
time factors (103) 103
indoles - therapeutic use (101) 101
levodopa (101) 101
molecular structure (101) 101
plant extracts - pharmacology (101) 101
research (100) 100
antiparkinson agents - adverse effects (99) 99
rats, sprague-dawley (98) 98
apoptosis - drug effects (96) 96
neurology (96) 96
oncology (96) 96
benzothiazoles - chemical synthesis (95) 95
chemistry, multidisciplinary (95) 95
toluene - analogs & derivatives (94) 94
benzothiazoles - metabolism (93) 93
chemistry, organic (91) 91
care and treatment (90) 90
picrates - chemistry (89) 89
rats, wistar (86) 86
cell proliferation - drug effects (84) 84
biphenyl compounds - chemistry (83) 83
cell biology (83) 83
abridged index medicus (82) 82
expression (82) 82
aged, 80 and over (81) 81
inhibitors (81) 81
toluene - pharmacology (80) 80
cell survival - drug effects (79) 79
dopamine agonists - pharmacology (78) 78
antioxidant (75) 75
antioxidants - chemistry (74) 74
antioxidant activity (73) 73
benzothiazoles - pharmacokinetics (73) 73
p53 (71) 71
proteins (71) 71
severity of illness index (71) 71
sleep (70) 70
plant extracts - chemistry (69) 69
research article (69) 69
sulfonic acids - metabolism (69) 69
free radical scavengers - pharmacology (68) 68
tumor suppressor protein p53 - metabolism (67) 67
antineoplastic agents - chemistry (66) 66
dopamine agonists (66) 66
dopamine agonists - administration & dosage (66) 66
toxicology (66) 66
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1809) 1809
German (17) 17
Russian (16) 16
Japanese (11) 11
Spanish (10) 10
French (4) 4
Hungarian (2) 2
Italian (2) 2
Dutch (1) 1
Hebrew (1) 1
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 05/2012, Volume 484, Issue 7397, pp. 260 - 263
Journal Article
Science, ISSN 0036-8075, 05/2016, Volume 352, Issue 6288, pp. aad3018 - aad3018
Macrophages accumulate with glioblastoma multiforme (GBM) progression and can be targeted via inhibition of colony-stimulating factor-1 receptor (CSF-1R) to... 
B-CELLS | INSULIN | MACROPHAGE PLASTICITY | GLIOBLASTOMA | MULTIDISCIPLINARY SCIENCES | IN-VIVO | GROWTH | RECEPTOR | CENTRAL-NERVOUS-SYSTEM | CANCER | PROGRESSION | Human Umbilical Vein Endothelial Cells | Receptor, IGF Type 1 - antagonists & inhibitors | Humans | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Pyrazines - therapeutic use | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Neoplasms, Experimental - immunology | Imidazoles - therapeutic use | Macrophages - immunology | Picolinic Acids - pharmacology | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor - antagonists & inhibitors | Neoplasm Recurrence, Local - metabolism | Signal Transduction | Benzothiazoles - pharmacology | NFATC Transcription Factors - metabolism | Neoplasms, Experimental - therapy | Imidazoles - pharmacology | STAT6 Transcription Factor - metabolism | Mice, Inbred Strains | Tumor Microenvironment - immunology | Animals | Glioblastoma - immunology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Picolinic Acids - therapeutic use | Macrophages - drug effects | Benzothiazoles - therapeutic use | Mice | Glioblastoma - drug therapy | Pyrazines - pharmacology | Insulin-Like Growth Factor I - antagonists & inhibitors | Insulin-Like Growth Factor I - metabolism | Cancer therapies | Brain cancer | Tumors | Index Medicus
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 08/2014, Volume 85, Issue 8, pp. 840 - 845
Journal Article
The Journal of Neuropsychiatry and Clinical Neurosciences, ISSN 0895-0172, 01/2010, Volume 22, Issue 1, pp. 8 - 18
This manuscript reviews the preclinical in vitro, ex vivo, and nonhuman in vivo effects of psychopharmacological agents in clinical use on cell physiology with... 
TRIALS | APOPTOSIS | DEMENTIA | PSYCHIATRY | ALZHEIMERS-DISEASE | NEUROSCIENCES | CLINICAL NEUROLOGY | PARKINSONS-DISEASE | Neuroprotective Agents - therapeutic use | Humans | Dopamine Agonists - therapeutic use | Parkinson Disease - drug therapy | Neurodegenerative Diseases - drug therapy | Valproic Acid - pharmacology | Desipramine - pharmacology | Dibenzothiazepines - therapeutic use | Neuroprotective Agents - pharmacology | Desipramine - therapeutic use | Antipsychotic Agents - therapeutic use | Amyloid beta-Peptides - metabolism | Valproic Acid - therapeutic use | Parkinson Disease - metabolism | Clonazepam - therapeutic use | Maprotiline - pharmacology | Dopamine Agonists - pharmacology | Benzodiazepines - pharmacology | Benzothiazoles - pharmacology | Brain - physiopathology | Dibenzothiazepines - pharmacology | Quetiapine Fumarate | Serotonin Uptake Inhibitors - therapeutic use | Alzheimer Disease - drug therapy | Clonazepam - pharmacology | Neurodegenerative Diseases - metabolism | Brain - drug effects | Lithium Carbonate - therapeutic use | Antioxidants - therapeutic use | Neurodegenerative Diseases - physiopathology | Lithium Carbonate - pharmacology | Alzheimer Disease - metabolism | Melatonin - therapeutic use | Benzothiazoles - therapeutic use | Maprotiline - therapeutic use | Antipsychotic Agents - pharmacology | Serotonin Uptake Inhibitors - pharmacology | Benzodiazepines - therapeutic use
Journal Article
Science Translational Medicine, ISSN 1946-6234, 03/2015, Volume 7, Issue 279, pp. 279ra40 - 279ra40
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 03/2012, Volume 49, pp. 324 - 333
Journal Article
Haematologica, ISSN 0390-6078, 2015, Volume 100, Issue 3, pp. E77 - E79
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 07/2014, Volume 120, Issue 14, pp. 2142 - 2149
Secondary FLT3‐tyrosine kinase domain mutations can arise after treatment with FLT3 inhibitors in patients with FLT3‐internal tandem duplication–mutated acute... 
FLT3 inhibitors | FLT3‐ITD | FLT3‐TKD | acute myeloid leukemia | secondary FLT3 mutations | FLT3-TKD | FLT3-ITD | MOLECULAR-MECHANISM | INTERNAL TANDEM DUPLICATION | INTENSIVE CHEMOTHERAPY | ACUTE MYELOGENOUS LEUKEMIA | RISK MYELODYSPLASTIC SYNDROME | TYROSINE KINASES | OLDER PATIENTS | ONCOLOGY | LESTAURTINIB CEP701 | THERAPEUTIC TARGET | PROGNOSTIC-SIGNIFICANCE | Niacinamide - analogs & derivatives | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | fms-Like Tyrosine Kinase 3 - genetics | DNA Mutational Analysis | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Antineoplastic Agents - pharmacology | Retrospective Studies | Medical Records | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Leukemia, Myeloid, Acute - mortality | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Aged | Benzothiazoles - therapeutic use | Carbazoles - therapeutic use | Protein Kinase Inhibitors - pharmacology | Mutation | Leukemia, Myeloid, Acute - genetics | Protein-Tyrosine Kinases - antagonists & inhibitors | Care and treatment | Myelocytic leukemia | Gene mutations | Analysis | Protein tyrosine kinase | Nonlymphoid leukemia | Research | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Sleep Medicine, ISSN 1550-9389, 02/2010, Volume 6, Issue 1, pp. 85 - 95
of Recommendations: Modifying the sleep environment is recommended for the treatment of patients with RBD who have sleep-related injury. Level A Clonazepam is... 
Paroxetine | Melatonin | Desipramine | Benzodiazepine | Clozapine | Clonazepam | Sleep-related injury | Sodium oxybate | Carbamazepine | Pramipexole | REM sleep behavior disorder | Zopiclone | Acetylcholinesterase inhibitor | Synucleinopathy | L-DOPA | Yi-Gan San | synucleinopathy | NEURODEGENERATIVE DISEASE | DEMENTIA | pramipexole | ALZHEIMERS-DISEASE | DOPAMINE TRANSPORTERS | sleep-related injury | desipramine | CLINICAL NEUROLOGY | DELAYED EMERGENCE | sodium oxybate | STATUS DISSOCIATUS | clonazepam | benzodiazepine | PARKINSONS-DISEASE | LEWY-BODY DISEASE | zopiclone | acetylcholinesterase inhibitor | DRUG-TREATMENT | carbamazepine | paroxetine | clozapine | EYE-MOVEMENT SLEEP | melatonin | Clonazepam - administration & dosage | REM Sleep Behavior Disorder - therapy | Central Nervous System Depressants - adverse effects | Humans | Dopamine Agonists - therapeutic use | GABA Modulators - administration & dosage | GABA Modulators - adverse effects | Dopamine Agonists - adverse effects | GABA Modulators - therapeutic use | Melatonin - administration & dosage | REM Sleep Behavior Disorder - drug therapy | Melatonin - adverse effects | Clonazepam - adverse effects | Central Nervous System Depressants - therapeutic use | Central Nervous System Depressants - administration & dosage | Dopamine Agonists - administration & dosage | Melatonin - therapeutic use | Benzothiazoles - therapeutic use | Clonazepam - therapeutic use | Benzothiazoles - adverse effects | REM Sleep Behavior Disorder - diagnosis | Benzothiazoles - administration & dosage | Index Medicus | Special
Journal Article
Cancer Research, ISSN 0008-5472, 02/2011, Volume 71, Issue 4, pp. 1418 - 1430
Journal Article